NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The primary advantage of synthetic bone graft substitutes and growth factors compared with allograft bone tissue is that they do not depend on the availability of donated human tissue. In addition, owing to the potential risk of disease transmission, synthetic materials and growth factors may be perceived as safer than allograft-based bone tissue. Many new composite products are also becoming available which seek to harness the combined characteristics of synthetic and natural materials in one single product optimised for rapid bone repair and regeneration.
Stem cell therapy is also showing huge potential as an alternative to autograft. Mesenchymal stem cells (MSCs) found in bone marrow, can form a variety of cells in the laboratory, including fat cells, cartilage, bone, tendon and ligaments, muscles cells, skin cells and even nerve cells. Unlike most other human adult stem cells, MSCs can be obtained in quantities appropriate for clinical applications, making them good candidates for use in tissue repair. They also offer the advantage of low morbidity and cost.
The last twelve months has seen consolidation in the orthobiologic sector, although most of the acquisitions have been relatively small in terms of money. The largest acquisition